Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINDACT breast cancer adjuvant treatment decision trial
2005-002625-31Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, capecitabine, letrozole, tamoxifen and cyclophosphamide in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Treatment decision randomization. Started Sep 2006; status: completed.
02
Drugs
docetaxelcapecitabineletrozoletamoxifencyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-002625-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002625-31.